Trial of Feedback on Blood Use
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | September 2014 |
End Date: | August 2016 |
Contact: | Richard M Kaufman, MD |
Email: | rmkaufman@partners.org |
Phone: | 617-732-4749 |
Trial of Feedback on Blood Use (TOFU)
The TOFU study will represent the first attempt to rigorously assess the impact of
audit-feedback on changing transfusion practice. The primary hypothesis is that providing
individual feedback on transfusion practice to orthopedic surgeons will reduce elective RBC
transfusions in the postoperative period.
TOFU is a two-arm, cluster-randomized controlled trial. Initially, baseline blood use data
will be collected at all study sites. Next, the PI at each site will give a short
educational presentation to the orthopedic surgeons. The presentation will consist of a
standardized 10-minute presentation reviewing the data from the FOCUS trial and the
recommended red blood cell (RBC) transfusion trigger of 8 g/dL (or symptomatic anemia) based
on that data. Clusters of orthopedic surgeons will then be randomized to either the Control
arm (no feedback) or the Intervention arm (monthly feedback). All of the surgeons at a given
site will either receive or not receive feedback. The feedback will take the form of emailed
monthly reports detailing blood use by each surgeon post-hip surgery. Surgeons will be
anonymized in the reports as "A, B, C . . ." but each surgeon will know which data are his
own. The primary end point is the decrease from baseline in the proportion of patients
transfused with a pretransfusion hemoglobin of > 8 g/dL.
TOFU will be conducted at 8 sites in Europe and North and South America. Care has been taken
to minimize the labor and costs required to conduct this study. The only data collected will
be: patient age/gender; procedure; surgeon (anonymized); surgery & discharge dates; RBC
units transfused; Hgb levels. The data will be entered at each site into a web-based Case
Report Form, and will be stored centrally by the Data Coordinating Center (DCC). The DCC
will generate monthly feedback reports and email them to each Intervention arm site PI. The
site PI will then email the reports to each local orthopedic surgeon.
The TOFU study will represent the first attempt to rigorously assess the impact of
audit-feedback on changing transfusion practice. The primary hypothesis is that providing
individual feedback on transfusion practice to orthopedic surgeons will reduce elective RBC
transfusions in the postoperative period.
TOFU is a two-arm, cluster-randomized controlled trial. Initially, baseline blood use data
will be collected at all study sites. Next, the PI at each site will give a short
educational presentation to the orthopedic surgeons. The presentation will consist of a
standardized 10-minute presentation reviewing the data from the FOCUS trial and the
recommended red blood cell (RBC) transfusion trigger of 8 g/dL (or symptomatic anemia) based
on that data. Clusters of orthopedic surgeons will then be randomized to either the Control
arm (no feedback) or the Intervention arm (monthly feedback). All of the surgeons at a given
site will either receive or not receive feedback. The feedback will take the form of emailed
monthly reports detailing blood use by each surgeon post-hip surgery. Surgeons will be
anonymized in the reports as "A, B, C . . ." but each surgeon will know which data are his
own. The primary end point is the decrease from baseline in the proportion of patients
transfused with a pretransfusion hemoglobin of > 8 g/dL.
TOFU will be conducted at 8 sites in Europe and North and South America. Care has been taken
to minimize the labor and costs required to conduct this study. The only data collected will
be: patient age/gender; procedure; surgeon (anonymized); surgery & discharge dates; RBC
units transfused; Hgb levels. The data will be entered at each site into a web-based Case
Report Form, and will be stored centrally by the Data Coordinating Center (DCC). The DCC
will generate monthly feedback reports and email them to each Intervention arm site PI. The
site PI will then email the reports to each local orthopedic surgeon.
Inclusion Criteria:
- Patients >= 18 years old undergoing total hip arthroplasty or hip hemiarthroplasty
Exclusion Criteria:
- Refusal of blood transfusions
- Surgeons utilizing "fast track" protocols (planned discharge on postoperative day 1
or 2 following surgery.)
We found this trial at
7
sites
Seattle, Washington 98101
Principal Investigator: Meghan Delaney, DO
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Claudia Cohn, MD, PhD
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Richard M Kaufman, MD
Phone: 617-732-4749
Click here to add this to my saved trials
1801 N Broad St
Philadelphia, Pennsylvania 19122
Philadelphia, Pennsylvania 19122
(215) 204-7000
Principal Investigator: Yanhua Li, MD
Temple University Temple University is many things to many people. A place to pursue life's...
Click here to add this to my saved trials
Click here to add this to my saved trials
St. Louis, Missouri 63110
Principal Investigator: Ronald Jackups, MD, PhD
Phone: 314-362-1252
Click here to add this to my saved trials